RESUMEN
A role of human papilloma virus (HPV) vaccines as a therapy for genital warts was suggested, nevertheless; it has not been established in clinical trials and has yet to be determined. The objective of this study is to evaluate a potential benefit of intralesional injection of bivalent HPV (Cervarix) vaccine as a treatment for anogenital warts versus topical podophyllin resin 25%. Forty-four patients with anogenital warts were included in the study, 22 patients received intralesional Cervarix every 2 weeks until clearance of lesions or for a maximum of five sessions. The other 22 patients received topical podophyllin resin 25% twice weekly until complete resolution or for a maximum of 4 weeks. Follow up was done for 6 months. Dermatology life quality index (DLQI) was measured. Complete clearance of warts was achieved in 10 patients (45.5%) in Cervarix group versus six patients (27.3%) in Podophyllin group. The difference was statistically insignificant. No recurrence of warts was reported in Cervarix group while two patients (33.3%) showed recurrence in Podophyllin group. Both treatments were well tolerated. All patients reported significant improvement of their DLQI. Intralesional Cervarix is a promising modality showing higher rates of complete response, high safety, and no recurrence.
Asunto(s)
Condiloma Acuminado , Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Verrugas , Condiloma Acuminado/tratamiento farmacológico , Humanos , Inyecciones Intralesiones , Infecciones por Papillomavirus/tratamiento farmacológico , Vacunas contra Papillomavirus/efectos adversos , Proyectos Piloto , Podofilino/efectos adversos , Verrugas/tratamiento farmacológicoRESUMEN
Patients often request treatment of their burdensome cutaneous warts. However, a safe and effective treatment for cutaneous warts is lacking. This study evaluates treatment outcome, side effects, and patient satisfaction after topical application of cantharidin 1% podophyllin 2% salicylic acid 30% (CPS1) solution in a large series of children and adults with cutaneous warts. Fifty-two children and 83 adults with warts, treated with CPS1 solution between October 2012 and October 2014, were included. Complete clearance of warts occurred in 86.5% of children and 62.7% of adults treated with CPS1 solution (p < .01). Resolution of warts was partial in 3.9 and 24.1% and absent in 9.6 and 13.2% of children and adults respectively. Side effects were present in 41.2% of children and 46.3% of adults (p = .7). Most common side effects were blistering, pain, and burning sensation. No serious adverse events occurred. On a 10-point scale, median patient satisfaction score was 9.0 (interquartile range 7.8-10.0) and 8.0 (interquartile range 5.1-9.7) for children and adults respectively (p < .01). CPS1 solution is a safe and promising treatment modality with a high clearance and high patient satisfaction rate for the management of cutaneous warts, particularly in children.
Asunto(s)
Cantaridina/administración & dosificación , Podofilino/administración & dosificación , Ácido Salicílico/administración & dosificación , Verrugas/tratamiento farmacológico , Administración Cutánea , Adulto , Factores de Edad , Cantaridina/efectos adversos , Niño , Estudios de Cohortes , Femenino , Humanos , Queratolíticos/administración & dosificación , Queratolíticos/efectos adversos , Masculino , Satisfacción del Paciente , Podofilino/efectos adversos , Estudios Retrospectivos , Ácido Salicílico/efectos adversos , Resultado del TratamientoRESUMEN
AIM: Zinc sulfate is beneficial in the treatment of epithelial warts. We conducted this study to compare the efficacy of combination therapy of oral zinc sulfate with conventional treatments in the treatment of vulvar warts. MATERIAL AND METHODS: This study was a randomized controlled trial. The sample size was 42 in each group. Women aged 20-50 years were placed by the block randomized method into six groups: the podophyllin-, imiquimod- and cryotherapy-treated groups, and another three groups receiving 8-week combination therapy of 400 mg oral zinc sulfate with one of the above-mentioned treatments. Data were analyzed using anova and Fischer's exact test with spss16. RESULTS: A total of 228 patients were recruited and completed the study in six treatment groups. No significant difference was observed in the response to treatment among these groups. Relapse after 6 months was significantly higher in the podophyllin-, imiquimod- and cryotherapy-treated patients compared to patients receiving these treatments in combination with oral zinc sulfate (P<0.05). CONCLUSIONS: Combined therapy of oral zinc sulfate with conventional treatments of vulvar warts appears to reduce the relapse rate.
Asunto(s)
Aminoquinolinas/uso terapéutico , Condiloma Acuminado/tratamiento farmacológico , Criocirugía , Podofilino/uso terapéutico , Enfermedades de la Vulva/tratamiento farmacológico , Sulfato de Zinc/uso terapéutico , Administración Cutánea , Administración Oral , Adulto , Aminoquinolinas/administración & dosificación , Aminoquinolinas/efectos adversos , Astringentes/administración & dosificación , Astringentes/efectos adversos , Astringentes/uso terapéutico , Terapia Combinada , Condiloma Acuminado/prevención & control , Condiloma Acuminado/cirugía , Criocirugía/efectos adversos , Femenino , Humanos , Imiquimod , Inductores de Interferón/administración & dosificación , Inductores de Interferón/efectos adversos , Inductores de Interferón/uso terapéutico , Irán , Queratolíticos/administración & dosificación , Queratolíticos/efectos adversos , Queratolíticos/uso terapéutico , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Podofilino/administración & dosificación , Podofilino/efectos adversos , Prevención Secundaria , Crema para la Piel , Enfermedades de la Vulva/prevención & control , Enfermedades de la Vulva/cirugía , Adulto Joven , Sulfato de Zinc/administración & dosificación , Sulfato de Zinc/efectos adversosAsunto(s)
Antineoplásicos Fitogénicos/efectos adversos , Enfermedades de la Córnea/inducido químicamente , Podofilino/efectos adversos , Administración Tópica , Adulto , Enfermedades de la Córnea/tratamiento farmacológico , Dolor Ocular/inducido químicamente , Dolor Ocular/tratamiento farmacológico , Neoplasias de los Párpados/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Humanos , Masculino , Papiloma/tratamiento farmacológico , Fotofobia/inducido químicamente , Fotofobia/tratamiento farmacológico , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Trastornos de la Visión/inducido químicamente , Trastornos de la Visión/tratamiento farmacológico , Agudeza Visual/fisiologíaRESUMEN
A 40-year-old woman presented with a delusion of warts on the forehead, for which she was applying podophyllin toxin. A skin biopsy was taken, which showed prominent mitotic figures in the basal and suprabasal layers of the epidermis and apoptotic keratinocytes. Histopathologically Bowen's disease was suspected, but was discounted after clinicopathological correlation was obtained and showed absence of epidermal atypia or disorganization. This case demonstrates the histological resemblance of podophyllin reaction to Bowen's disease. Differentiation of self-inflicted from organic skin disease may be difficult, especially where histopathological findings are confounded by cutaneous application of toxins.
Asunto(s)
Enfermedad de Bowen/diagnóstico , Cáusticos/efectos adversos , Deluciones/psicología , Paraqueratosis/inducido químicamente , Podofilino/efectos adversos , Verrugas/psicología , Adulto , Cáusticos/administración & dosificación , Diagnóstico Diferencial , Femenino , Humanos , Paraqueratosis/patología , Podofilino/administración & dosificación , Dermatosis del Cuero Cabelludo/diagnóstico , Dermatosis del Cuero Cabelludo/psicología , Automedicación , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/psicología , Verrugas/prevención & controlRESUMEN
Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin-the purified, standardised active antiwart ingredient of podophyllin-represents safe and effective first line therapy for patients with anogenital warts.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Queratolíticos/efectos adversos , Fototerapia/efectos adversos , Podofilino/efectos adversos , Femenino , Humanos , Queratolíticos/uso terapéutico , Extractos Vegetales/efectos adversos , Extractos Vegetales/uso terapéutico , Podofilino/uso terapéutico , Podofilotoxina/efectos adversos , Podofilotoxina/uso terapéuticoRESUMEN
Pre-clinical studies indicate that cisplatin encapsulated in STEALTH((R))liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity, compared to native cisplatin. A phase I study was conducted to determine the toxicity and pharmacokinetics of SPI-77 administered to children with advanced cancer not amenable to other treatment. Paediatric patients were treated at doses ranging from 40 to 320 mg m(-2)by intravenous infusion every 4 weeks. Blood samples taken during, and up to 3 weeks after, administration and plasma and ultrafiltrate were prepared immediately. Urine was collected, when possible, for 3 days after administration. SPI-77 administration was well tolerated with the major toxicity being an infusion reaction which responded to modification of the initial infusion rate of SPI-77. Limited haematological toxicity and no nephrotoxicity were observed. No responses to treatment were seen during the course of this phase I study. Measurement of total plasma platinum showed that cisplatin was retained in the circulation with a half life of up to 134 h, with maximum plasma concentrations approximately 100-fold higher than those reported following comparable doses of cisplatin. Comparison of plasma and whole blood indicated that cisplatin was retained in the liposomes and there was no free platinum measurable in the ultrafiltrate. Urine recovery was less than 4% of the dose administered over 72 h. Results from this phase I study indicate that high doses of liposomal cisplatin can safely be given to patients, but further studies are required to address the issue of reformulation of liposomally bound cisplatin.
Asunto(s)
Antineoplásicos/farmacocinética , Cisplatino/farmacocinética , Neoplasias/tratamiento farmacológico , Podofilino/análogos & derivados , Podofilino/farmacocinética , Adolescente , Antineoplásicos/efectos adversos , Área Bajo la Curva , Niño , Preescolar , Colesterol/sangre , Cisplatino/efectos adversos , Cisplatino/sangre , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Lactante , Lípidos/sangre , Lipoproteínas HDL/sangre , Lipoproteínas HDL/efectos de los fármacos , Lipoproteínas LDL/sangre , Lipoproteínas LDL/efectos de los fármacos , Liposomas , Masculino , Neoplasias/metabolismo , Podofilino/efectos adversos , Podofilino/sangre , Podofilotoxina/análogos & derivados , Factores de Tiempo , Triglicéridos/sangreRESUMEN
AIM: The aims of this study were to: 1) ascertain if podophyllin resin in 0.5% [PE(0.5%)] and 0.25% [PE(0.25%)] in ethanol (PE) self-applied sequentially for 3 days with 4 days break cycle is as effective as supervised podophyllin 25% in tincture benzoin (PB) applied in the clinic biweekly in treating penile warts and 2) ascertain if PE causes less skin irritation than PB. METHODS AND RESULTS: The clearance rate of penile warts was 36.4% (4/11) in PE (0.5%) treated group, 66.7% (4/6) in the PE (0.25%) treated group and 33.3% (6/18) for PB treated group after 1 week (ns). The wart clearance rate at 6 weeks for PE (0.5%) treated group, PE (0.25%) treated group and PB treated group were 81.8% (9/11), 100% (6/6) and 83.3% (15/17) respectively (ns). There were 47 individual warts on the penis of the 17 patients in the PE treated group and 58 individual warts on the penis of the 18 patients in the PB treated group. Based on the response of individual warts to the 2 treatment regimens, the clearance rate was 42.6% (20/47) for the PE treated group and 25% (15/56) for the PB treated group after 1 week treatment (ns). At 6 weeks follow-up, the clearance rate for the PE treated group and the PB treated group were 85.1% (40/47) and 73.2% (41/56) respectively (ns). Skin irritation including superficial erosions, pain and itch were observed in 47% (8/17) in patients treated with PE compared to 38.9% (7/18) in patients treated with PB (ns) during the 6 weeks follow-up period. The clearance rate of patients treated with PE (0.25%) was compared to those treated with PE (0.5%). Four out of six of PE (0.25%) treated patients had clearance of warts after 1 week and 100% clearance at the end of 6 weeks. None experienced any skin irritation. CONCLUSION: This study demonstrates that 0.5% podophyllin (and possibly 0.25% podophyllin) in ethanol is effective in eradicating penile warts. It can be used by patients for self-treatment at home with greater convenience and is more cost effective than the conventional podophyllin 25% in tincture benzoin paint.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Queratolíticos/administración & dosificación , Enfermedades del Pene/tratamiento farmacológico , Podofilino/administración & dosificación , Adulto , Anciano , Emolientes , Etanol , Humanos , Queratolíticos/efectos adversos , Masculino , Persona de Mediana Edad , Extractos Vegetales , Podofilino/efectos adversos , Solventes , StyraxRESUMEN
OBJECTIVE: To compare the effectiveness and cost of self treatment of penile warts with a commercial preparation of podophyllotoxin 0.5% (PDX 0.5%) with podophyllin 0.5% and podophyllin 2.0% sourced from Podophyllum emodii. DESIGN: A prospective double blind randomised study. SUBJECTS: 315 patients with penile warts attending two departments of genitourinary medicine. MAIN OUTCOME MEASURES: Absence of warts, cessation of treatment due to severe side effects at 5 weeks. RESULTS: Of the 315 patients, 244 conformed to the protocol. Analysis was on an intention to treat basis. At 5 weeks no significant differences were found in the extent of healing of warts or in side effects for the three treatment groups. The costs of drug treatment (excluding staff time) are at least pounds 10.00 less for podophyllin than podophyllotoxin. A fourfold variation in the active constituents of the podophyllin preparations did not produce appreciably different clinical responses. In a subanalysis no evidence of deterioration in effectiveness of podophyllin over time was demonstrated. CONCLUSIONS: Penile warts in selected cases can be safely treated with 0.5-2.0% podophyllin self applied by the patient at a fraction of the cost of commercially available podophyllotoxin. The shelf life of the podophyllin extracts is at least 3 months. These findings may be especially relevant in countries where resources for health care are limited.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Queratolíticos/administración & dosificación , Enfermedades del Pene/tratamiento farmacológico , Podofilino/administración & dosificación , Método Doble Ciego , Estabilidad de Medicamentos , Humanos , Queratolíticos/efectos adversos , Masculino , Enfermedades del Pene/virología , Podofilino/efectos adversos , Podofilotoxina/administración & dosificación , Podofilotoxina/efectos adversos , Estudios Prospectivos , AutoadministraciónAsunto(s)
Antineoplásicos/efectos adversos , Síndrome de Cushing/inducido químicamente , Podofilino/análogos & derivados , Antineoplásicos/uso terapéutico , Artritis/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Podofilino/efectos adversos , Podofilino/uso terapéutico , Podofilotoxina/análogos & derivadosRESUMEN
The treatment of genital warts with cytodestructive agents such as podophyllin and trichloroacetic acid continues to impose a heavy burden on the workload of genitourinary medicine clinics. Consequently clinics are now looking to new, economical treatments that will improve the management of patients with genital warts. The most promising of these new agents is podophyllotoxin, which is now available in pharmaceutically pure form tailored for the home treatment of external genital warts in males and females.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Enfermedades del Pene/tratamiento farmacológico , Podofilotoxina/uso terapéutico , Enfermedades Vaginales/tratamiento farmacológico , Enfermedades de la Vulva/tratamiento farmacológico , Contraindicaciones , Femenino , Humanos , Masculino , Podofilino/efectos adversos , Podofilino/uso terapéutico , Podofilotoxina/administración & dosificación , Podofilotoxina/efectos adversos , Embarazo , AutoadministraciónAsunto(s)
Quemaduras Químicas/etiología , Podofilino/efectos adversos , Vulvitis/inducido químicamente , Adolescente , Adulto , Condiloma Acuminado/tratamiento farmacológico , Femenino , Enfermedades de los Genitales Femeninos/inducido químicamente , Humanos , Errores de Medicación , Autoadministración/efectos adversosRESUMEN
Proresid, mainly consisting of podophyllotoxin derivatives and two glycosides thereof, has been used as a disease-modifying antirheumatic drug in Sweden since the late 1960s. A life-table analysis of Proresid treatment averaging 41 months (range 4-144) in 79 rheumatoid arthritis patients showed a termination rate of 40, 56, 75 and 85% after 1/2, 1, 2 and 4 years, respectively. Dominant reasons for discontinuing therapy were inefficacy (37%) and gastrointestinal symptoms (35%). The risk of discontinuation of therapy due to inefficacy was constant over time, while the risk due to other causes, including side effects, gradually decreased. A comparison with injectable gold therapy showed, after adjusting for confounding factors, that the total termination incidence was higher (p < 0.05) in the Proresid-treated patients. A comparison with the regional cancer register of 334 patients exposed to Proresid for a mean time of 2.2 years showed no increased cancer risk after a mean observation time of 6.1 years.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Oro/administración & dosificación , Podofilino/análogos & derivados , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Artritis Reumatoide/complicaciones , Estudios de Cohortes , Femenino , Oro/uso terapéutico , Humanos , Incidencia , Inyecciones , Tablas de Vida , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Neoplasias/epidemiología , Cooperación del Paciente , Pacientes Desistentes del Tratamiento , Podofilino/efectos adversos , Podofilino/uso terapéutico , Podofilotoxina/análogos & derivados , Pronóstico , Factores de Riesgo , Resultado del TratamientoRESUMEN
Os autores realizam uma revisäo das informaçöes atuais e já consolidadas a respeito do fármaco, mostrando suas propriedades farmacodinâmicas e farmacocinéticas, suas indicaçöes e problemas associados e, completando, informaçöes de interesse do médico generalista e do paciente na aplicaçäo fora do consultório. Por fim, säo apresentadas opçöes terapêuticas para o tratamento de sua principal indicaçäo, o condiloma acuminado.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Podofilino/uso terapéutico , Condiloma Acuminado/terapia , Podofilino/administración & dosificación , Podofilino/efectos adversos , Podofilino/farmacologíaRESUMEN
Topical agents that do not produce irritant reaction elsewhere on the skin readily produce irritant dermatitis and even ulceration when applied to scrotal skin. As Shelley and Shelley state: "The scrotum must be recognized as a skin area with remarkable permeability. It provides a unique percutaneous doorway for the entrance of drugs into the circulation and is thus uniquely susceptible to toxic and irritant agents."